GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Gross Profit

ACHFF (Arch Biopartners) Gross Profit : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Arch Biopartners Gross Profit?

Arch Biopartners's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Arch Biopartners's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Arch Biopartners's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Arch Biopartners's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Arch Biopartners's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Arch Biopartners had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Arch Biopartners Gross Profit Historical Data

The historical data trend for Arch Biopartners's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Gross Profit Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 - - - -

Arch Biopartners Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arch Biopartners's Gross Profit

For the Biotechnology subindustry, Arch Biopartners's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Gross Profit distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Gross Profit falls into.



Arch Biopartners Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Arch Biopartners's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as

Gross Profit (A: Sep. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Arch Biopartners's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Arch Biopartners's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Arch Biopartners  (OTCPK:ACHFF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Arch Biopartners had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Arch Biopartners Gross Profit Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners Business Description

Traded in Other Exchanges
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

Arch Biopartners Headlines

From GuruFocus